Braveheart Bio, Inc.

For the period ended Jun 30, 2026. Filed Sep 8, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Sep 8, 2026

BRVE$19.62+0.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Statements of Operations and Comprehensive Loss

Condensed Statement of Operations and Comprehensive Loss (unaudited)

(in thousands, except share and per share amounts)

	Three Months Ended		Six Months Ended
	June 30,2026	June 30,2025	June 30,2026	June 30,2025
Operating expenses
Research and development (includes related party amounts of $389 and $6,389 for the three and six months ended June 30, 2026, respectively)	$11,125	$—	$22,039	$—
In-process research and development	—	354	—	448
General and administrative (includes nominal related party amounts for the three and six months ended June 30, 2026, respectively)	4,757	27	8,892	32
Total operating expenses	15,882	381	30,931	480
Loss from operations	(15,882)	(381)	(30,931)	(480)
Other income
Interest income	889	—	1,660	—
Other income	5	—	3	—
Total other income	$894	$—	$1,663	$—
Net loss	$(14,988)	$(381)	$(29,268)	$(480)
Deemed dividends upon issuance of redeemable convertible preferred stock	(3,615)	—	(3,615)	—
Net loss attributed to common stockholders	$(18,603)	$(381)	$(32,883)	$(480)
Net loss per share, basic and diluted	$(2.51)	$(0.14)	$(4.61)	$(0.34)
Weighted-average shares of common stock outstanding, basic and diluted	7,401,783	2,792,409	7,133,871	1,403,918

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.